Laurion Capital Management LP Prometheus Biosciences, Inc. Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $24,313 - $29,678	-235 Reduced 0.12%	195,663 $21 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $1.14 Million - $3.71 Million	-31,610 Reduced 13.89%	195,898 $21.5 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $18,564 - $38,887	-659 Reduced 0.29%	227,508 $13.4 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $2.24 Million - $3.89 Million	-100,000 Reduced 30.47%	228,167 $6.44 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $3.55 Million - $6.3 Million	159,369 Added 94.41%	328,167 $13 Million
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $2.23 Million - $2.88 Million	106,714 Added 171.89%	168,798 $4 Million
Q2 2021 Aug 13, 2021	BUY	$16.8 - $29.65 $203,011 - $358,290	12,084 Added 24.17%	62,084 $1.53 Million
Q1 2021 May 14, 2021	BUY	$16.51 - $25.29 $825,500 - $1.26 Million	50,000 New	50,000 $913,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.